We are committed to finding effective treatment for life-threatening infectious diseases.
A Game Changer in Antibacterials Treatment for Gram-negative bacteria, Ultimate Target of N-Rephasin® Technology
Eco-friendly, no Side-effects, Unique mode of action. Bacteriophages and Antibiotic Resistance in Bacteria
New Generation of Heme-Iron (Porphyrin-Fe) Novel concept iron deficiency anemia therapeutic agent
iNtRON Biotechnology held the corporate presentation for private and institutional investors on February 19, 2019. The purpose of the corporate presentation was to increase shareholders’ understanding about the company and investment value. During the corporate presentation, Seong Jun Yoon, CEO & Founder, made a presentation regarding......
Roivant plans to initiate Phase 2 clinical trial in 2019 Agreement includes option to in-license additional anti-Gr(+) programs Roivant Sciences and iNtRON Biotechnology today announced that they have entered into a global licensing agreement for SAL200, a novel investigational biologic for the treatment of......
iNtRON Biotechnology has announced that N-Rephasin BAL200 for the treatment of anthrax infection has been received Orphan Drug Designation (ODD) from the US Food and Drug Administration (US FDA). Orphan Drug Designation is a program of FDA to support for the new drug development of rare......
iNtRON Bio has been focusing on the R&D investment since its foundation and accelerate development speed after the IPD in KOSDAQ. We are aiming for the ‘global R&D company’ ; and promoting the value of the company focused on the BIO New Drug by developing various ‘First-in-Class’ bio-drugs and conducting clinical studies in phases.
